| Name | Topside Manor Inc |
|---|---|
| Location | 208 W 2nd Street, Goodland, Kansas |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 45 |
| Occupancy Rate | 79.33% |
| Medicare ID (CCN) | 175361 |
| Legal Business Name | Topside Manor Inc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1548827397 |
| Organization Name | TOPSIDE MANOR INC |
| Address | 208 W 2nd St, Goodland, KS 67735 |
| Phone Number | 785-890-7517 |
News Archive
Side effects associated with several commonly-prescribed dementia drugs may be putting elderly Canadians at risk, says Queen's University Geriatrics professor Sudeep Gill.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.
Though some view it as a difficult sell, new advertising from the 17 states that are setting up health insurance marketplaces tends to be upbeat and positive. First Lady Michelle Obama is also pitching in on efforts to reach very specific populations.
Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a gene for endurance, or more precisely, a negative regulator of it.
› Verified 6 days ago
| NPI Number | 1801886338 |
| Organization Name | THE EVANGELICAL LUTHERAN GOOD SAMARITAN SOCIETY |
| Doing Business As | GOOD SAMARITAN SOCIETY - SHERMAN COUNTY |
| Address | 208 W 2nd St, Goodland, KS 67735 |
| Phone Number | 785-890-7517 |
News Archive
Side effects associated with several commonly-prescribed dementia drugs may be putting elderly Canadians at risk, says Queen's University Geriatrics professor Sudeep Gill.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.
Though some view it as a difficult sell, new advertising from the 17 states that are setting up health insurance marketplaces tends to be upbeat and positive. First Lady Michelle Obama is also pitching in on efforts to reach very specific populations.
Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a gene for endurance, or more precisely, a negative regulator of it.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Side effects associated with several commonly-prescribed dementia drugs may be putting elderly Canadians at risk, says Queen's University Geriatrics professor Sudeep Gill.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.
Though some view it as a difficult sell, new advertising from the 17 states that are setting up health insurance marketplaces tends to be upbeat and positive. First Lady Michelle Obama is also pitching in on efforts to reach very specific populations.
Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a gene for endurance, or more precisely, a negative regulator of it.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $10403 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 21.87 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 15.52 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 52.05 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 3 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 7.38 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.34 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.11 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 60.58 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.45 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 54.55 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.28 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 17.56 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.33 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.91 | 95.98 |